Insigneo Advisory Services LLC Sells 236 Shares of Zoetis Inc. (NYSE:ZTS)

Insigneo Advisory Services LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,023 shares of the company’s stock after selling 236 shares during the quarter. Insigneo Advisory Services LLC’s holdings in Zoetis were worth $818,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Mission Wealth Management LP lifted its holdings in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after buying an additional 59 shares in the last quarter. VeraBank N.A. lifted its stake in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after purchasing an additional 62 shares in the last quarter. HUB Investment Partners LLC boosted its holdings in Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after purchasing an additional 62 shares during the period. Procyon Advisors LLC grew its position in shares of Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators increased its holdings in shares of Zoetis by 6.6% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after purchasing an additional 65 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Morgan Stanley dropped their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Stifel Nicolaus cut their price objective on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Piper Sandler lifted their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Finally, StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus price target of $214.40.

Zoetis Stock Down 1.6 %

Shares of NYSE:ZTS opened at $146.78 on Thursday. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock’s 50-day moving average price is $161.02 and its 200-day moving average price is $170.60. The stock has a market capitalization of $65.49 billion, a P/E ratio of 26.83, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.36%. Zoetis’s payout ratio is currently 36.56%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 in the last quarter. Company insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.